NCT05469113View on ClinicalTrials.gov

A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

January 29, 2019

Primary Completion Date

March 5, 2019

Study Completion Date

March 5, 2019

Conditions
Healthy
Interventions
DRUG

Repaglinide

Administered orally.

DRUG

Selpercatinib

Administered orally.

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Collaborators (1)

Loxo Oncology, Inc.
All Listed Sponsors
collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT05469113 - A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants | Biotech Hunter | Biotech Hunter